ABSTRACT The biochemical basis for bleomycin-induced pulmonary toxicity was studied in vitro and in vivo with an improved HPLC system. The in vitro metabolism of bleomycin A2 to desamido-bleomycin A2 was measured in tissue homogenates from a species sensitive (mice) and relatively resistant (rabbits) to the pulmonary fibrogenic properties of bleomycin. Lung tissue from mice lacked detectable bleomycin hydrolase activity, whereas rabbit lung tissue homogenates had high levels of the enzyme activity, equaling that seen in rabbit kidneys and spleen. Injection of radiolabeled bleomycin A2 into mice demonstrated that only a small percentage of the total dose was taken up by any organ and that extensive metabolism of this drug occurred within 1 hr in liver, kidneys, and spleen but not in lungs in vivo. In addition, metabolites other than desamido-bleomycin A2 were prominent, and their relative amounts increased with time. Mice injected subcutaneously with bleomycin A2 developed pulmonary fibrosis, while animals treated with equivalent doses of desamido-bleomycin A2 did not, indicating that this metabolite is not as toxic to the lungs as is the parent compound. These results provide direct evidence that metabolism plays a major role in determining the toxic potential of bleomycin to the lungs.
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Bleomycin (BLM) is a glycoprotein that is extensively used in combination with other anticancer agents because of its relative lack of hematological and gastrointestinal toxicity. However, pulmonary toxicity is common with BLM and limits its therapeutic utility (1) . Life-threatening, irreversible pulmonary fibrosis is associated with high cumulative doses of BLM; thus, it is important to understand the biochemical basis of its lung toxicity. Furthermore, BLM may be a useful prototype for studying the general mechanism by which other substances, including anticancer drugs, cause pulmonary toxicity.
Cellular toxicity from BLM exposure is believed to result from interactions between the drug and DNA (2) . Although considerable attention has been directed toward understanding these interactions, comparatively little is known about the biochemical mechanism responsible for tumor sensitivity and host toxicity to this drug. BLM can be metabolized by an aminopeptidase B-like enzyme activity, BLM Previous experiments (4-7) indicated that repeated injections of mice with 5-10 mg of BLM per kg of body weight for 4 weeks or more produced pulmonary fibrosis as detected by an increase in lung hydroxyproline content and by histological analyses, whereas a similar injection protocol failed to yield fibrosis in rabbits (8) . The experiments reported here examined the relative BLM hydrolase activities in various organs of these two species to evaluate the hypothesis of Umezawa et al. (3) . A modification of our recently described sensitive HPLC system for detection of BLM B2 and desamido-BLM B2 (9) was used. In addition, the metabolism of radiolabeled BLM A2 in organs of mice in vivo and the pulmonary toxicity of the only previously described metabolite of BLM A2, desamido-BLM A2 (BLM dA2), were determined.
MATERIALS AND METHODS Drugs. BLM (Blenoxane) and Cu-free BLM A2 that were used as HPLC standards were obtained from W. T. Bradner (Bristol Laboratories, Syracuse, NY). The Cu-free metabolite of BLM A2, BLM dA2 (lot TN-A-029), that was used as a standard was supplied by A. Fujii (Nippon Kayaku, Tokyo, Japan). The BLM used in the enzyme assays and in vivo studies was obtained from Blenoxane by the procedures of Roy et al. (10) . The BLM dA2 injected into mice was synthesized by incubating 15 mg of Cufree BLM A2 for 24 hr at 370C with 5 ml (125 mg of protein) of the rabbit liver homogenate used for BLM hydrolase activity assays. After 24 hr, the reaction mixture was centrifuged through a CF-25 Centriflo cone (Amicon) at 1,000 x g for 30 min at 40C to remove any unreacted BLM A2 and the product, BLM dA2. The material remaining in the cone was resuspended twice with 6 ml of glass-distilled water and centrifuged. The filtrates were pooled and purified on a CM-Sephadex column by the method of Roy et al. (10) . Based (Fig. 2A) . In contrast, the BLM hydrolase activity in mouse lung homogenates was below the detection limits of our assay (Fig. 2B) . Mouse liver, spleen, and kidney homogenates all had detectable levels of BLM hydrolase activity.
In Vivo Results. The total radioactivity in selected organs, serum, and urine of mice at various times after injection of [3H]-BLM A2 was measured. Urine contained at least 10-fold more radioactivity than serum at all times examined (Fig. 3) . Consistent with previously reported values for the serum half-life of BLM A2 (13), a serum half-life of =50 min was observed for [3H]BLM A2. The radioactivity in kidneys greatly exceeded that seen in liver, spleen, and lungs at all time points examined, and at 1 hr there was 8-fold more radioactive material in the kidneys than in any of these other organs. In liver, lungs, and spleen, peak levels of radioactivity appeared at -1 hr, and each of these organs had similar dpm per mg of wet weight.
To evaluate the nature of the radioactivity in each organ of mice, we next used our HPLC system. One hour after subcutaneous treatment with [3H]BLM A2, >95% of the total radioactivity in serum and urine comigrated with authentic [3H]-BLM A2 (fractions 34-36; Fig. 4 A and B) . In kidney samples (Fig. 4C) , prominent peaks appeared at fractions 34-36 (BLM A2) and at fractions 28-29 (BLM dA2). Additional peaks also were seen in the void volume (fractions [12] [13] [14] and at fractions 25-26. In liver tissue (Fig. 4D) The HPLC profile of the metabolites in organs changed with time after injection. For example, in kidney samples a decrease in BLM A2 relative to the other metabolites was seen over the 2-hr period (Fig. 5 A-D (Fig. 6) . Liver, spleen, and kidneys showed extensive metabolism at 1 hr, with >45% of the drug being metabolized. In contrast, only 10% of the drug in lungs appeared as metabolites. The metabolite formation increased in all organs over time, with liver, spleen, and kidneys having 55% or more of the radiolabel as metabolites at 2 hr. In contrast, the maximum metabolism seen in mouse lungs in-vivo was only 23%.
To evaluate the ability of the only previously known metabolite of BLM A2, BLM dA2, to cause pulmonary fibrosis, we injected mice for 6 weeks twice weekly with NaCl/KCI/Pi or 10 mg of BLM A2 or dA2 per kg. Previous studies (5, 6) indicated that this dose schedule of BLM produced increases in lung hydroxyproline, a marker of collagen content, and histological evidence of increased collagen. In the lungs of mice treated with 10 mg of BLM A2 per kg, there was clear evidence of fibrosis demonstrated by a 31% increase in the pulmonary hydroxyproline content (Table 1) and by an increased presence of collagen observable after staining with Masson's trichrome (data not shown). In contrast, a similar treatment with BLM dA2 did not cause fibrosis as defined by our biochemical and morphological methods, although some lung consolidation and hypercellularity was seen in the lungs of mice treated with BLM dA2. BLM A2 was quite toxic to mice as seen by the significant decrease in total body weight; this was not observed in mice treated with BLM dA2. DISCUSSION Umezawa et aL (3, 14) hypothesized that pulmonary toxicity occurred in lungs rather than other organs because the lungs were deficient in their ability to inactivate BLM. This conclusion was based upon observations with a bioassay that measured antimicrobial activity. Other investigators (13) indicated, however, that microbiological bioassays for BLM content are not only laborious but also insensitive. More important, in a bioassay some organs that do not display drug-induced toxicity appeared unable to inactivate BLM in vitro. Consequently, the relationship between antimicrobial activity and host organ toxicity is not clear. Umezawa et aL (3, 14) also suggested that inactivation was due to the formation of a deaminated compound by an aminopeptidase B-like enzyme activity, BLM hydrolase. The deaminated form of BLM is the only reported metabolite and, although it is thought to be less potent in causing DNA strand breaks (15) , its toxicity, particularly to lung tissue, has not been studied previously.
Recently, HPLC systems have been used to study BLM metabolism, but these have relied upon UV absorption, which lacked the sensitivity to measure nanogram quantities of drug. The HPLC system described here for BLM A2 is at least 10-fold more sensitive than those not using spectrofluorescence (9) and permits measurement of enzyme activity with less tissue or substrate. Using this HPLC system, we have observed that in organ homogenates from a species that has been shown to be sensitive to BLM-induced pulmonary fibrosis (4-7), the lung BLM hydrolase activity is at least 5-to 15- (15) . In addition, our results indicate that BLM dA2 is much less potent in producing pulmonary fibrosis than is the parent compound. Thus, high levels of BLM hydrolase activity in lung tissue would protect the lungs from the toxic effects of BLM. This appears to occur in rabbit lungs. Therefore, the results of this study indicate (i) that BLM A2 is extensively metabolized in most tissues examined, (ii) that metabolites other than BLM dA2 are formed in vivo, and (iii) that, based upon in vitro and in vivo data, the sensitivity of the lungs to BLM-induced toxicity can best be explained by the lack of BLM hydrolase activity.
One of the major problems with the clinical use of BLM is identification of patients that may be susceptible to drug-induced fibrosis. No reliable methods to identify patients at risk are available. Once pulmonary fibrosis occurs, it is difficult to control and may be irreversible and life-threatening (1) . The HPLC technique we have described for measuring BLM hydrolase activity in vitro is both sensitive and rapid; <100 mg of tissue is required. Therefore, it may be possible in the future to biopsy human lungs and assay BLM hydrolase activity prior to therapy to determine if the enzyme activity is related to the sensitivity of each patient to BLM-induced pulmonary fibrosis.
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